PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY- COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN ...
Abstract
Authors
W Herring IG Gould L Ruiz T Dort Y Zhang C Acosta R Hyde T Spelman H Butzkueven